Preparation and in vitro evaluation of fused deposition modeling 3D printed compound tablets of captopril and hydrochlorothiazide / 北京大学学报(医学版)

OBJECTIVE@#To explore the feasibility of preparing compound tablets for the treatment of hypertension by fused deposition modeling (FDM) 3D printing technology and to evaluate the quality of the printed compound tablets in vitro.@*METHODS@#Polyvinyl alcohol (PVA) filaments were used as the exci-pient to prepare the shell of tablet. The ellipse-shaped tablets (the length of major axes of ellipse was 20 mm, the length of the minor axes of ellipse was 10 mm, the height of tablet was 5 mm) with two separate compartments were designed and printed using FDM 3D printer. The height of layer was 0.2 mm, and the thickness of roof or floor was 0.6 mm. The thickness of shell was 1.2 mm, and the thickness of the partition wall between the two compartments was 0.6 mm. Two cardiovascular drugs, captopril (CTP) and hydrochlorothiazide (HCT), were selected as model drugs for the printed compound tablet and filled in the two compartments of the tablet, respectively. The microscopic morphology of the tablets was observed by scanning electron microscopy (SEM). The weight variation of the tablets was investigated by electronic scale. The hardness of the tablets was measured by a single-column mechanical test system. The contents of the drugs in the tablets were determined by high performance liquid chromatography (HPLC), and the dissolution apparatus was used to measure the in vitro drug release of the tablets.@*RESULTS@#The prepared FDM 3D printed compound tablets were all in good shape without printing defects. The average weight of the tablets was (644.3±6.55) mg. The content of CTP and HCT was separately (52.3±0.26) mg and (49.6±0.74) mg. A delayed in vitro release profile was observed for CTP and HCT, and the delayed release time for CTP and HCT in vitro was 20 min and 40 min, respectively. The time for 70% of CTP and HCT released was separately 30 min and 60 min.@*CONCLUSION@#CTP and HCT compound tablets were successfully prepared by FDM 3D printing technology, and the printed tablets were of good qualities.

Comparación de los perfiles de disolución de comprimidos de lamotrigina de 100mg comercializados en Paraguay / Comparison of the dissolution profiles of tablets of lamotrigine 100mg traded in Paraguay

Objetivo: evaluar los perfiles de disolución decomprimidos de Lamotrigina 100mg (Test) con laReferencia (Lamictal®) comercializados en Paraguay.Material y Métodos: Se utilizaron comprimidosde Lamotrigina de 100mg comercializados enParaguay. Se determinaron los perfiles de disoluciónde los productos Test y Referencia, en los tresmedios de disolución recomendados (pHs 1,2 ; 4,5y 6,8). El método analítico se basó en HPLC condetector PDA a 277nm, usando una PhenomenexLuna C18 a 40ºC, con fase móvil de buffer fosfatode sodio 0.05M pH4.0-acetonitrilo (80:20), flujode 1.3mL/min y tiempo de retención de 5 min.Resultados: Los perfiles de disolución del productoTest de Lamotrigina 100mg, fueron similaresen los diferentes pHs al producto de Referencia,liberando más del 85% a los 15 minutos en los 3medios de disolución, no siendo necesaria la comparacióncon el factor f2.Conclusión: Los perfiles de disolución de los comprimidosde Lamotrigina de 100mg Test muestranun comportamiento in vitro semejante al productode Referencia, lo que sugiere que su comportamientoin vivo podría ser también semejante.

Objectives: to evaluate the dissolution profiles ofLamotrigine tablets of 100 mg (Test) and Reference(Lamictal®) marketed in Paraguay.Material and Methods: Tablets of Lamotrigine100 mg marketed in Paraguay were used. Dissolutionprofiles of the Test and Reference productswere determined in the three recommended dissolutionmedia (pH 1.2; 4.5 and 6.8). The HPLCmethod used consisted of a Phenomenex Luna C18column, with mobile phase of 0.05M sodium phosphatebuffer pH4.0-acetonitrile (80:20), flow rateof 1.3mL / min and retention time of 5 min. Thecolumn compartment was kept at 40ºC, and thewavelength detection was 277 nm.Results: The dissolution profiles of the Test productof Lamotrigine 100mg, showed similar behavior tothe Reference product at the three different pHs,releasing more than 85% in 15 minutes in the threemedia dissolution. No calculation using the similarityfactor f2 was needed.Conclusion: Dissolution profiles of the two formulationsof Lamotrigine 100mg were similar in thedifferent pH dissolution media, thus a similar invivo behavior could be expected.

The use of the software JST-XRD for identification of crystalline phases in pharmaceutical raw materials and tablets / Uso do software JST-XRD para identifcação de fases cristalinas em insumos farmacêuticos e medicamentos

Study of polymorphism is of great importance for the pharmaceutical industry once polymorphs may display different physicochemical properties, which, in turn, may result in stability differences that can bring problems for the manufacturing stages and the quality of fnal products. Although research on organic polymorphs has greatly increased in the last decades, it still does not cover all needs for the pharmaceutical market. Techniques such as spectroscopy in the infrared region, nuclear magnetic resonance, thermal analysis, X-ray diffraction, etc., can be used to identify polymorphism. The polymorphism is a property of the crystalline solid state, and can be evaluated by X-ray diffraction once each polymorph exhibits one specifc X-ray diffraction pattern. The JST-XRD program is a tool designed to help the identifcation of crystalline phases (including polymorphs) present in pharmaceutical ingredients and tablets by using X-ray diffraction data obtained from scientifc articles and patents. This paper presents new implementations for the JST-XRD and describes its use in the analysis of active pharmaceutical ingredient and marketed tablets of norfloxacin, mebendazole and atorvastatin calcium. By the means of comparison, JSTXRD allowed identifying the crystalline phases in the diffraction patterns of the analyzed drugs, showing the program suitability for polymorphism research, pre-formulation and quality control in pharmaceutical industries. JST-XRD can also be used for educational purposes in undergraduate and graduate programs in order to show the potentiality of X-ray powder diffraction in polymorphism analysis.(AU)

O estudo do polimorfsmo é de grande importância na indústria farmacêutica porque os polimorfos podem apresentar diferentes propriedades físico-químicas, podendo resultar em diferenças na estabilidade e desse modo causar problemas nas etapas de manufatura e no produto fnal. Embora a pesquisa de moléculas orgânicas que apresentam polimorfsmo tenha aumentado bastante nas últimas décadas, ainda não contempla todas as necessidades do mercado farmacêutico. Para a identifcação de polimorfsmo podem ser utilizadas técnicas como espectroscopia na região do infravermelho, ressonância nuclear magnética, análise térmica (DSC), difração de raios X, etc. O polimorfsmo, por ser uma propriedade do estado sólido e cristalino, pode ser avaliado através da difração de raios X, já que cada polimorfo apresenta um padrão de difração de raios X único. O programa JST-XRD é uma ferramenta projetada para auxiliar a identifcação de fases cristalinas, incluindo polimorfos, presentes em insumos farmacêuticos e comprimidos, usando dados de difração de raios X obtidos em artigos científcos e patentes. Esse trabalho apresenta novas implementações no JST-XRD e descreve seu uso na análise de amostras de princípio ativo e comprimidos comerciais de norfloxacino, mebendazol e atorvastatina cálcica. Através das comparações realizadas, JSTXRD permitiu identifcar todas as fases cristalinas dos difratogramas dos fármacos analisados, mostrando que o programa é adequado para pesquisa em polimorfsmo; na pré-formulação e controle de qualidade em indústrias farmacêuticas, assim como para uso didático em cursos de graduação e pós-graduação a fm de mostrar as potencialidades da difração de raios X na análise de polimorfsmo.(AU)

Shock séptico en unidad de cuidados intensivos: Enfoque actual en el tratamiento / Septic shock in intensive care units: Current focus on treatment

Los pilares terapéuticos del niño con shock séptico se mantienen en el tiempo, sin embargo, se han incorporado nuevos conceptos, siendo importante que el pediatra y el intensivista tengan conocimiento a cabalidad de ellos. La reanimación con fluidos es una intervención fundamental, no obstante, aún no se ha establecido un tipo de fluido ideal, presentando cada uno limitaciones específicas, no existiendo evidencia sobre la superioridad de un tipo de fluido. Si a pesar de una adecuada resucitación con fluidos persiste el shock, el inicio de inótropos y/o vasopresores está indicado. En caso de refractariedad al uso de vasopresores, nuevos fármacos vasoactivos pueden ser empleados y el uso de hidrocortisona debe considerarse en niños con sospecha de insuficiencia suprarrenal. Existe controversia respecto a la transfusión de glóbulos rojos o el nivel óptimo de glucemia, no existiendo consenso en el valor umbral para el uso de estos hemocomponentes o el inicio de insulina, respectivamente. Asimismo, la utilización de la hemofiltración de alto volumen (HFAV)aún permanece controversial, requiriendo mayores estudios para su recomendación en forma rutinaria en el curso de un shock séptico refractario. El soporte nutricional es primordial, ya que la desnutrición es una grave complicación que debe ser prevenida y tratada adecuadamente. El objetivo de la presente revisión es entregar una actualización en los más recientes avances en tratamiento del shock séptico en la población pediátrica.

Essential therapeutic principles in children with septic shock persist over time, although some new concepts have been recently incorporated, and fully awareness of pediatricians and intensivists is essential. Fluid resuscitation is a fundamental intervention, but the kind of ideal fluid has not been established yet, as each of these interventions has specific limitations and there is no evidence supportive of the superiority of one type of fluid. Should septic shock persists despite adequate fluid resuscitation, the use of inotropic medication and/or vasopressors is indicated. New vasoactive drugs can be used in refractory septic shock caused by vasopressors, and the use of hydrocortisone should be considered in children with suspected adrenal insufficiency, as it reduces the need for vasopressors. The indications for red blood cells transfusion or the optimal level of glycemia are still controversial, with no consensus on the threshold value for the use of these blood products or the initiation of insulin administration, respectively. Likewise, the use of high-volume hemofiltration is a controversial issue and further study is needed on the routine recommendation in the course of septic shock. Nutritional support is crucial, as malnutrition is a serious complication that should be properly prevented and treated. The aim of this paper is to provide update on the most recent advances as concerns the treatment of septic shock in the pediatric population.

Formulation of gastroretentive floating drug delivery system using hydrophilic polymers and its in vitro characterization

The aim of the present research is to formulate and evaluate the gastroretentive floating drug delivery system of antihypertensive drug, propranolol HCl. Gastroretentive floating tablets (GRFT) were prepared by using a synthetic hydrophilic polymer polyethylene oxide of different grades such as PEO WSR N-12 K and PEO 18 NF as release retarding polymers and calcium carbonate as gas generating agent. The GRFT were compressed by direct compression strategy and the tablets were evaluated for physico-chemical properties, in vitro buoyancy, swelling studies, in vitro dissolution studies and release mechanism studies. From the dissolution and buoyancy studies, F 9 was selected as an optimized formulation. The optimized formulation followed zero order rate kinetics with non-Fickian diffusion mechanism. The optimized formulation was characterised with FTIR studies and observed no interaction between the drug and the polymers.

O objetivo da presente pesquisa é o de formular e avaliar o sistema de liberação de fármaco gastrorretentivo flutuante, contendo o anti-hipertensivo, cloridrato de propranolol. Comprimidos gastrorretentivo flutuantes (GRFT) foram preparados utilizando um polímero hidrofílico sintético, o óxido de polietileno, de diferentes graus, tais como GE WSR N-12 K e GE 18 NF, como polímeros de retardamento de liberação, e carbonato de cálcio, como agente gerador de gases. Os GRFT foram comprimidos por compressão direta e avaliados para determinação das propriedades físico-químicas, flutuabilidade in vitro, estudos de inchamento, de dissolução in vitro e de mecanismo de liberação. Dos testes de dissolução e de flutuabilidade, selecionou-se F 9 como formulação otimizada. A formulação otimizada seguiu cinética de ordem zero, com mecanismo de difusão não-Fickiano. Essa formulação foi caracterizada por estudos de FTIR, não se observando interação entre o fármaco e os polímeros.

Physico-chemical comparison of famotidine tablets prepared via dry granulation and direct compression techniques

Famotidine is generally employed for the treatment of gastric ulcer. The present study was conducted to fabricate famotidine tablets using various diluents. The binder was incorporated to the formulations in different proportions. Both the dry granulation and direct compression techniques were employed to develop the tablets. Physical evaluation of tablets i.e. tablets hardness, friability, weight variation, thickness and diameter was determined. In vitro dissolution studies of the prepared tablets were carried out for 60 min using the USP apparatus II and 900 ml 0.1 M HCl stirred at 37 +/- 0.5[degree sign] C with a speed of 50 rpm. Physical analysis of tablets prepared via direct compression showed satisfactory results regarding the weight variation, hardness and friability, since their respective values were within the BP limits. All the prepared famotidine tablets exhibited diffusion based mode of drug release. 100% release of drug occurred in less than 60 min. The drug release from all the formulated tablets has elaborated the involvement of diffusion [Higuchian drug release]. This comparative study exhibited that physical parameters of tablets are affected by the technique of tabletting

Preparation, characterization and tableting of cilnidipine solid dispersions

Solid dispersion technique has been developed many years for improving solubility of water-insoluble drugs, aiming to achieve a better oral bioavailability. However, this technique exhibits many inconveniences when used for large-scale tableting procedures. The objective of current research work was to develop cilnidipine solid dispersions [SDs] to improve the dissolution behaviors of this water-insoluble drug. Moreover, an innovative granulation method was designed to simplify the traditional tableting technology used in solid dispersion technique. Three different kinds of polymers, polyethylene glycol [PEG], polyvinylpyrrolidone [PVP] and poloxamer, were used as carriers to prepare solid dispersions. The interactions in the solid state were characterized by differential scanning calorimetry [DSC], powder Xray diffraction [PXRD] and FT-IR spectroscopy. The designed granulation method was employed to prepare solid dispersion tablets and the formulation was optimized through investigating the dissolution behaviors. The results indicated PEG solid dispersion showed the best effect both on physical characterizations and dissolution studies. Furthermore, all type of solid dispersions significantly improved the dissolution rates when compared to pure drug and its corresponding physical mixture [PM]. The solid dispersion tablets prepared in simplified tableting method exhibited better operability, stability and dissolution behavior than the tablets prepared in traditional ways, which brought more opportunities to solid dispersion technique for industrial production

[Separation and assay of metronidazole and diloxanid furoate in tablets by RP-HPLC]

A reverse phase high performance liquid chromatography method was developed for the determination of diloxanide furoate and metronidazole in tablets. The separation was achieved using C8 column [4.6 mm x 250 mm] 5 micro m and mobile phase acetonitrite: water [65:35] v/v, at a flow rate of 1ml/min. Detection was carried out using UV at 230 nm. The retention times of metronidazole and diloxanide furoate were 3.17 and 5.18 min. the detection limits for metronidazole and diloxanide furoate were 0.03, 0.04 micro g/ml and the Quantitation limits were 0.11, 0.13 micro g/ml respectively. The method has validated for accuracy, precision, selectivity and robustness, Linearity was in the range of 32 - 48 micro g/ml for metronidazole, and 40 -60 micro g/ml for diloxanide furoate. The recovery values of Accuracy were 99.08 - 100.52% for metronidazole and diloxanide furoate respectively

Modificación de formas farmacéuticas sólidas: relevamiento en un hospital de la Provincia de Córdoba / [Modification of solid dosage forms: survey in a hospital of the Province of Cordoba].

BACKGROUND: In the hospital setting is frequent to manipulate solid dosage forms (SDF, tablets 16 and capsules), which can affect their physicochemical and biopharmaceutical properties, the pharmacoloeffect and sometimes to cause the appearance of undesirable side effects. OBJECTIVES: To identify the medicines whose SDF is altered in a Hospital of Cordoba (Argentina), to determine how these modifications are made and to establish whether they were properly performed or not. METHODS: We retrospectively analyzed the prescriptions made between the 5th and the 11th of March of 2012 and identified impaired requesting SDF modifications. Open interviews were held with nurses and service visits to each hospital to determine how they manipulated the SDF. RESULTS: We analyzed 700 prescriptions for 113 patients, of which 61 (54

) had manipulations of the received SDF (49 for medical prescription, 7 because they had nasogastric tubes, 3 due to patient choice and 2 by nursing decision). Twenty three medicines were manipulated, but only 12 were correctly manipulated. The major changes were partition of tablets and grinding of tablets or microgranules and dispersible in water. CONCLUSION: The SDF of several medicines is altered in the analyzed hospital, many times without medical indication and scientific justification. It would be appropriate to conduct training courses and establish closer collaborations between pharmacy and nursing units in the investigated hospital.

Study of compressibility properties of yogurt powder in order to prepare a complementary formulation

The aim of the present study was to prepare an oral tablet from liquid yogurt by reforming the physical properties for easy transportation, long-term storage and also as a complementary dairy product in case of nutrient deficiency. The liquid fresh yogurt was lyophilized at -40°C and 0.03 mTor pressure. The dry powder was homogenized by a 12 mesh size sieve. Some tests such as Carr's compressibility index, Hausner ratio and the angle of repose were applied to evaluate the flowability of yogurt powder. Study of the deformation of particles during forcing was done by calculation of the elastic recovery index. Carr's compressibility index percent and Hausner ratio were calculated 15 and 0.94, respectively. The range of repose angle was measured between19-20. The elastic recovery was obtained up to 60%. Since the hardness of tablets increased by decreasing compression velocity, therefore yogurt powder might have a plastic deformation. The reduction of powder volume due to compression force was about 20% [p < 0.05]. Tablets with low fat yogurt showed very good compressibility with 6-12 Strong-Cab [SC] hardness units. Producing a complementary formulated as a tablet from yogurt powder is possible and also maybe therapeutically effective against lactose-intolerance syndrome and preventing antibiotic-associated diarrhea.We suggest that for more authentic confirmation of the type of deformation, it should go through Heckel's equation analysis, too

Simultaneous determination of losartan and hydrochlorothiazide in pharmaceutical preparations by derivative and ratio derivative spectrophotometry

Losartan is a non-peptide potent antihypertensive agent that acts through blocking angiotensin n receptors. Hyzaar is a combination product that contains two drugs, losartan and hydrochlorothiazide, used to lower high blood pressure. There are some reports regarding simultaneous measurement of the drugs in pharmaceutical and biological samples which includes HPLC, CE, CEC, and multisyringe chromatography. UV-V is spectra of standard solutions of losaratan and hydrochlorothiazide were prepared separately and together in combination with various concentrations of the drugs. To determine these two drugs simultaneously without any preliminary treatment, losartan was determined by ratio derivative Spectrophotometry at third derivation with ? lamda = 10 nm at 246.3 nm, and hydrochlorothiazide was determined at first derivation with delta lamda = 5nm at 334.4 nm. This method was used to determine the two drugs in real samples of tablets. The method had a good linearity in the concentration range studied [r > 0.999]. Precision of the method revealed that RSD% was lower than 2.10 and 1.79 for losartan and hydrochlorothiazide, respectively. Accuracy of the method on the basis of error% was lower than 3.3% for losartan and 2.3% for hydrochlorothiazide. Based on the validation results, it could be concluded that the method was reliable and valid for determination of the drugs in their preparations. Real sample analysis showed that tablets had 84.9% hydrochlorothiazide and 92.6% losartan compared to label amount of the drugs. Results depicted a simple, valid, inexpensive and reliable method for simultaneous determination of the two drugs in pharmaceutical preparations applicable to the quality control laboratory of pharmaceutical industries

Interaction study of moxifloxacin and lomefloxacin with co-administered drugs

Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections. Fluoroquinolones are known to have interactions with drugs that are active in gastro intestinal tract. Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. The interaction was studied at neutral, acidic and basic conditions both at room temperature and 37°C. The effect of dissolution medium simulating various body environments with response to pH has been examined in order to elucidate the interactions. The response of moxifloxacin and lomefloxacin after interaction with co-administered drugs at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector. It was seen that interaction of these fluoroquinolones was more at 37°C than at room temperature. Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. The study ensures the interaction of fluoroquinolones with selected class of drugs. In order to achieve the effective therapeutic effect appropriate time intervals between administrations of drugs is essential

Preparation of cross-linked carboxymethyl jackfruit starch and evaluation as a tablet disintegrant

The main purposes of this study are to prepare cross-linked carboxymethyl jackfruit starch [CL-CMJF] and to evaluate its pharmaceutical property as a tablet disintegrant. CL-CMJF was prepared by a dual carboxymethyl-crosslinking reaction in a flask containing jackfruit seed starch [JFS], chloroacetic acid [CAA], sodium hydroxide [NaOH] and sodium trimetaphosphate [STMP]. The reaction was carried out using methanol as a solvent for 60 min at 70°C and at JFS:CAA:NaOH:STMP ratio of 1.0:0.29:0.28:0.07. The obtained CL-CMJF, with degree of substitution and degree of crosslinking calculated to be 0.34 and 0.06, respectively, was insoluble but swellable in water. Rheological study revealed a decreased in solution viscosity compared to the non-crosslinked CMJF. The water uptake of CL-CMJF was 23 times higher than that of native starch and was comparable to that of a commercial superdisintegrant, sodium starch glycolate [SSG]. The swelling ability of CL-CMRS was similar to that of crosscarmellose sodium [CCS], another commercial superdisintegrant. Disintegration test of aspirin tablets containing 2%w/w of JFS, CL-CMJF, SSG and CCS showed disintegration times in the order of SSG < CCS CL-CMJF <<< JFS. The results suggested that CL-CMJF could be developed as a tablet disintegrant

Development and implication of a capillary electrophoresis methodology for ciprofloxacin, paracetamol and diclofenac sodium in pharmaceutical formulations and simultaneously in human urine samples

This work studies the development of a simple and fairly rapid methodology for simultaneous determination/ separation of three frequently co-administered drugs; ciprofloxacin [CIP], paracetamol [PCT] and diclofenac sodium [DIG] using capillary electrophoresis [CE] with UV detection at 260 nm. Separation was achieved in only 6.5 min with a simple buffer of sodium tetraborate [50 mM] at pH 9.0. The Parameters affecting the separation and detection were optimized. The calibration curves were linear in the range of 5-500 microg/mL for CIP, 5-250 micro g/mL for PCT and 1-125 microg/mL for DIC sodium under the optimized conditions. The lower limit of detection [LOD] was found to be 1 microg/mL for CIP and PCT and 0.5 microg/mL for DIC. The method was successfully used for the analysis of drugs in commercial pharmaceutical formulations and simultaneously from patient's urine sample with RSD 0.5-2.4%. Results obtained with CE method are compared with standard HPLC procedure and were found in good agreement

Development of a dissolution test for lamotrigine in tablet form using an ultraviolet method

A dissolution test for tablets containing 100 mg of lamotrigine was developed and validated. The dissolution test was applied to compare the dissolution profile of Neural® with the reference product Lamictal®. The analysis procedure was carried out using a simple ultraviolet method at 267 nm. After the determination of solubility and sink conditions, the parameters selected were paddles at 50 rpm, 900 mL of 0.01 M hydrochloric acid, and 30 minutes duration (single point). This method was validated for specificity, linearity, accuracy, precision and robustness. Lamotrigine stability was also evaluated in dissolution medium.

A finalidade deste estudo foi desenvolver e validar um método de dissolução para o fármaco lamotrigina na forma farmacêutica comprimido. Este método também foi utilizado para comparar o perfil de dissolução entre o Neural® e o produto de referência Lamictal®. O procedimento analítico foi realizado utilizando-se espectrofotometria de absorção no ultravioleta (267 nm) como forma de quantificação do fármaco. Após a determinação da solubilidade e das condições sink, os parâmetros selecionados foram: pás (50 rpm), 900 mL de ácido clorídrico 0.01 M e o tempo de 30 minutos (único ponto). Este método foi validado através da especificidade, linearidade, exatidão, precisão e robustez. A estabilidade da lamotrigina também foi avaliada no meio de dissolução.

Formulation and evaluation of mouth dissolving tablets of the etoricoxib

The demand for mouth dissolving tablets has been growing during the last decade especially for elderly and children who have swallowing difficulties. Etoricoxib is a new non-steroidal anti-inflammatory drug [NSAID] with selective cox-2 inhibitory activity, selective inhibition of cox-2 provides anti-inflammatory and analgesic activity it is commonly used for osteo-arthritis, rheumatoid arthritis, primary dysmenorrhoea, post operative dental pain and acute gout. The main criteria for mouth dissolving tablets are to disintegrate or dissolve rapidly in oral cavity with saliva in 15sec to 60sec with need of water. The disintegrants used should fulfill the criteria by disintegrating the tablets in specified time limit.in the present investigation variety of super disintegrants like primogel, kollidone, Ac-Di-sol, L-HPMC, L-HPC, were selected and tablets were prepared by direct compression method in different concentration like 4% and 8%. The prepared tablets were evaluated for weight variation, hardness, friability, in vitro disintegration time, wetting time, in vitro dissolution study, etc. formulation f-9 shows the lowest disintegration time [44sec] and wetting time [52sec]. In vitro dissolution studies revealed that formulation F-9 containning 8% L-HPC showed 97% drug release at the end of 20 min

Formulation and evaluation of cetirizine dihydrochloride orodispersible tablet

Cetirizine orodispersible tablets were prepared to achieve quick onset of action and for maximum bioavailability. Tablets were prepared using cetirizine along with camphor and mannitol in the proportion of 1:1:1, 1:1:3, and 1:1:6. The flow property of granules was found to be good for the formulation CZ2 [1:1:3]. The hardness and friability of all the formulations were found to be within the standard limit for orodispersible tablets. Disintegration time was found to be rapid in formulation CZ2 [1:1:3].The in vitro dissolution time was found to be 100% in 11 minutes for the formulation CZ2 [1:1:3]

In vitro bioequivalence study of nine brands of artesunate tablets marketed in Nigeria.

BACKGROUND & OBJECTIVES: The availability of numerous brands of artesunate in our drug market today places clinicians and pharmacists in a difficult situation of choice of a suitable brand or the possibility of alternative use. The aim of the present study was to predict the bioequivalence of nine brands of artesunate tablets marketed in Nigeria using in vitro tests. METHODS: The in vitro dissolution study was carried out on the nine brands of artesunate tablets using the basket method according to US Pharmacopoeia (USP) guidelines. Other general quality assessment tests like hardness and disintegration time were also determined. RESULTS: All the brands tested passed the British Pharmacopoeia (BP) standard for disintegration time. Only AT2, AT4, AT6 and AT9 passed the standard for hardness. There were significant differences in the dissolution profiles of the nine brands. All the brands except AT1, however, released >70% of artesunate within 30 min. Four of the brands AT5, AT6, AT7 and AT8 exhibited >90% dissolution in <10 min. The other brands AT1, AT2, AT3, AT4 and AT9 (innovator brand) have calculated similarity factors of 23.8, 59.8, 50, 54.8 and 100. INTERPRETATION & CONCLUSION: Based on the in vitro tests, AT5, AT6, AT7 and AT8 are considered bioequivalent and interchangeable, while AT2, AT3 and AT4 are considered bioequivalent and interchangeable with the innovator brand (AT9). AT1 has very low dissolution rate, which will likely result in poor bioavailability. The results show the need for constant monitoring of new brands of artesunate introduced into the drug market to ascertain bioequivalence and conformity with pharmacopoeia standards.

Perfil de dissolução in vitro de comprimidos de primaquina disponíveis para tratamento de malária no Brasil / In vitro dissolution profile of primaquine tablets available for malaria treatment in Brazil

A ineficácia clínica de muitos medicamentos tem servido de alerta para estudos mais profundos sobre os componentes da formulação, processos empregados e características físico-químicas dos fármacos. O objetivo deste trabalho foi avaliar a liberação in vitro de comprimidos de fosfato de primaquina disponíveis no Brasil para tratamento da malária, e o desenvolvimento de novas formulações de liberação convencional. Embora os comprimidos de fosfato de primaquina estudados tenham sido aprovados pelos critérios propostos pela Farmacopéia Americana (2006) para o teste de dissolução, não apresentaram desempenho adequado para o perfil de dissolução, mostrando retenção do fármaco durante a liberação. Os resultados indicam a existência de problemas nos comprimidos de fosfato de primaquina analisados, podendo sugerir como um dos fatores responsáveis pelo aparecimento de resistência dos parasitas.

The clinical inefficacy of many medications has served to highlight the need for deeper studies on the formulation components, processes used and physicochemical characteristics of drugs. The objective of this study was to evaluate the in vitro release of primaquine phosphate from tablets available in Brazil for treating malaria, and the development of new formulations for conventional release. Although the primaquine phosphate tablets studied had been approved according to the criteria proposed by the United States Pharmacopoeia (2006) for the dissolution test, they did not present adequate dissolution performance characteristics, in that there was drug retention during the release process. The results indicate the existence of problems in the primaquine phosphate tablets analyzed, and it may suggest that this is one of the factors responsible for the appearance of parasite resistance.

Influência das propriedades de granulados de celulose nas características físicas dos comprimidos / Influence of properties of cellulose granules on the physical characteristics of tablets

O comportamento de compactação dos sistemas sólidos particulados pode ser fortemente influenciado pelas características físico-químicas dos excipientes, pois muitas vezes, estes se apresentam em proporções maiores que o próprio fármaco, na formulação do comprimido. O objetivo deste estudo foi avaliar a influência do tamanho dos granulados de celulose nas características físicas de comprimidos obtidos em diferentes diâmetros de punção, considerando que esta relação não tem sido explorada na literatura. Diferentes tamanhos de granulados foram produzidos por granulação úmida e compactados em diferentes diâmetros de punção pela aplicação de diferentes forças. A distribuição de tamanho, as densidades aparentes e o fluxo dos granulados foram avaliados, bem como as características físicas dos comprimidos (peso, dureza, friabilidadee tempo de desintegração). A redução do tamanho dos granulados levou à obtenção de compactos com resistência mecânica adequada e rápida desintegração, além de permitir a produção dos comprimidos sem autilização de forças que representem o limite máximo do equipamento, o que deve evitar o desgaste precoce. Desta forma, ao selecionar o tamanho dos comprimidos adequados para determinada formulação, a escolha do tamanho dos granulados mostra-se determinante para a resistência mecânica dos compactos.